Reports Q2 revenue $31.24M, consensus $30.36M. “Our Q2 results were consistent with our expectations. We are making significant progress on our initiatives to expand our product portfolio, including launching our novel blood collection device for proteomic research in July. We are also staying closely aligned with our customers as they navigate an environment with improving, but still elevated, levels of uncertainty related to funding for public health programs and research,” said Carrie Eglinton Manner, president and CEO of OTI.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSUR:
- OraSure Technologies Reports 43% Revenue Decline in Q2 2025
- OraSure appoints Messing as Chief Commercial Officer
- OSUR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- OraSure received takeover bid from on Ron Zwanziger, Reuters reports
- OraSure bid between $3.50-$4.00 per share, Reuters says